US Stock MarketDetailed Quotes
BIVI BioVie
- 3.050
- -0.060-1.93%
Close Nov 22 16:00 ET
- 3.110
- +0.060+1.97%
Post 20:02 ET
54.19MMarket Cap-600P/E (TTM)
3.190High3.010Low2.16MVolume3.070Open3.110Pre Close6.68MTurnover15.34%Turnover RatioLossP/E (Static)17.77MShares56.20052wk High3.85P/B42.99MFloat Cap1.04052wk Low--Dividend TTM14.10MShs Float460.977Historical High--Div YieldTTM5.79%Amplitude1.040Historical Low3.089Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
BioVie Stock Forum
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
BioVie (NASDAQ: BIVI) announced the acceptance of an abstract detailing their planned Phase 2 trial of bezisterim for Long COVID treatment at the Demystifying Long COVID International Conference in Barcelona. The study, fully funded by the U.S. Department of Defense, will be a double-blind, randomized, placebo-controlled tri...
📊⚡️📊
Biovie’s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BioVie Inc (NASDAQ: BIVI) announced the pricing of a registered direct offering of 1,146,000 shares of common stock at $2.83 per share, aiming to raise approximately $3.2 million in gross proceeds. The offering, priced at-the-market under Nasdaq rules, is expected to close around October 29, 2024. The company plans to use the net proceeds for working capital and general corpo...
No comment yet